Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bone graft & orthobiologics cases in Connecticut: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 12% on average (190 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 7 | 323 | 46% |
| 2020 | 7 | 265 | 50% |
| 2021 | 8 | 272 | 53% |
| 2022 | 5 | 246 | 54% |
| 2023 | 6 | 224 | 57% |
| 2024 | 5 | 234 | 59% |
| 2025 from claims | – | 227 185–267 | 63% |
| 2026 forecast | – | 237 188–300 | 62% |
| 2027 forecast | – | 237 178–316 | 63% |
| 2028 forecast | – | 237 171–331 | 64% |
| 2029 forecast | – | 237 164–344 | 65% |
| 2030 forecast | – | 236 158–356 | 65% |
Graft add-on codes identify surgeons using biologics across spine and extremity cases. Professional codes (what the surgeon bills): CPT 20930, 20931, 20936, 20937, 20938, 20939.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Connecticut; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 69% inpatient hospital, 31% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 25 | 982−12%/yr | −12%/yr | 0.7 | 0% | 970 in 2030−0.2%/yr |
| New York | 21 | 761−4.9%/yr | −4.9%/yr | 0.4 | 1% | 770 in 2030+0.2%/yr |
| Massachusetts | 14 | 563−11%/yr | −11%/yr | 0.6 | 0% | 630 in 2030+1.9%/yr |
| New Jersey | 3 | 169−17%/yr | −17%/yr | 0.2 | 1% | 160 in 2030−0.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 174 | 34,341−4.3%/yr | −4.3%/yr | 98.51.1× | 31% | 42,800 in 2030+3.7%/yr |
| Skin substitutes & wound grafts | 15 | 3,005+7.9%/yr | +7.9%/yr | 5.31.1× | 50% | 4,060 in 2030+5.1%/yr |
Bone graft & orthobiologics in every state, and its device makers · Every procedure market in Connecticut · Every state · Compare with Pennsylvania
Johnson & Johnson MedTech leads with 17% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 13 companies reported engagement with Connecticut’s surgeons worth $135K in consulting, speaking, meals and travel tied to these products, about $27K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.